We take a look at the approval of Relyvrio, the third approved treatment for ALS, and the first to show both a slowing of disease progression and extended survival.
The Bionest team attended the American Academy of Neurology (AAN) in early May, where we heard exciting data presented in a number of neurological conditions. Among the highlights of this year’s conference: Transformative Success in Spinal Muscular Atrophy Spinal muscular atrophy (SMA) was a hot topic at AAN, with presentations of positive clinical...